Tysabri natalizumab regulatory update

Biogen Idec updated the U.S. label for autoimmune drug Tysabri natalizumab to warn

Read the full 139 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE